Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Accumulated Expenses (2016 - 2025)

Icu Medical (ICUI) has disclosed Accumulated Expenses for 17 consecutive years, with $315.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 2.74% year-over-year to $315.3 million, compared with a TTM value of $315.3 million through Dec 2025, up 2.74%, and an annual FY2025 reading of $315.3 million, up 2.74% over the prior year.
  • Accumulated Expenses was $315.3 million for Q4 2025 at Icu Medical, roughly flat from $316.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $325.7 million in Q3 2024 and bottomed at $79.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $239.3 million, with a median of $252.9 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses crashed 34.12% in 2021, then skyrocketed 231.18% in 2022.
  • Year by year, Accumulated Expenses stood at $118.2 million in 2021, then skyrocketed by 105.4% to $242.8 million in 2022, then increased by 10.48% to $268.2 million in 2023, then rose by 14.43% to $306.9 million in 2024, then increased by 2.74% to $315.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for ICUI at $315.3 million in Q4 2025, $316.1 million in Q3 2025, and $313.8 million in Q2 2025.